{
    "id": 23014,
    "fullName": "KIT V560_Y578del",
    "impact": "deletion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "KIT V560_Y578del results in the deletion of eighteen amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 560 to 578 (PMID: 12879016). V560_Y578del has not been characterized, however, similar Kit exon 11 deletions are activating, thus V560_Y578del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",
            "references": [
                {
                    "id": 2055,
                    "pubMedId": 12879016,
                    "title": "Signal transduction by several KIT juxtamembrane domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12879016"
                },
                {
                    "id": 650,
                    "pubMedId": 9438854,
                    "title": "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9438854"
                },
                {
                    "id": 2054,
                    "pubMedId": 15365079,
                    "title": "Biology of gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15365079"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "V560_Y578del",
    "createDate": "06/08/2016",
    "updateDate": "05/14/2019",
    "referenceTranscriptCoordinates": {
        "id": 136856,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54727447_54727503del57",
        "cDna": "c.1679_1735del57",
        "protein": "p.V560_Y578del19",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT V560_Y578del in culture (PMID: 25673643).",
            "molecularProfile": {
                "id": 23687,
                "profileName": "KIT V560_Y578del"
            },
            "therapy": {
                "id": 2284,
                "therapyName": "BGJ398 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6494,
                    "pubMedId": 25673643,
                    "title": "FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25673643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6798,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608).",
            "molecularProfile": {
                "id": 23687,
                "profileName": "KIT V560_Y578del"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16910,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HQP1351 treatment inhibited Kit activity and proliferation of a gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31673329).",
            "molecularProfile": {
                "id": 23687,
                "profileName": "KIT V560_Y578del"
            },
            "therapy": {
                "id": 8237,
                "therapyName": "HQP1351",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17819,
                    "pubMedId": 31673329,
                    "title": "Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31673329"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17531,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and downstream signaling, reduced proliferation and induced cell-cycle arrest in a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).",
            "molecularProfile": {
                "id": 23687,
                "profileName": "KIT V560_Y578del"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived GIST cell line harboring KIT V560_Y578del demonstrated sensitivity to Gleevec (imatinib) in culture (PMID: 25239608).",
            "molecularProfile": {
                "id": 23687,
                "profileName": "KIT V560_Y578del"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17563,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508).",
            "molecularProfile": {
                "id": 23687,
                "profileName": "KIT V560_Y578del"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6801,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) (PMID: 25239608).",
            "molecularProfile": {
                "id": 23692,
                "profileName": "KIT V560_Y578del KIT T670I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17533,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and downstream signaling, reduced proliferation, and induced cell-cycle arrest in a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del and KIT T670I in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).",
            "molecularProfile": {
                "id": 23692,
                "profileName": "KIT V560_Y578del KIT T670I"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6802,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608).",
            "molecularProfile": {
                "id": 23692,
                "profileName": "KIT V560_Y578del KIT T670I"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17566,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508).",
            "molecularProfile": {
                "id": 23692,
                "profileName": "KIT V560_Y578del KIT T670I"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).",
            "molecularProfile": {
                "id": 23693,
                "profileName": "KIT V560_Y578del KIT D816E"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).",
            "molecularProfile": {
                "id": 23694,
                "profileName": "KIT V560_Y578del KIT A829P"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23687,
            "profileName": "KIT V560_Y578del",
            "profileTreatmentApproaches": [
                {
                    "id": 8960,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT V560_Y578del"
                }
            ]
        },
        {
            "id": 23692,
            "profileName": "KIT V560_Y578del KIT T670I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23693,
            "profileName": "KIT V560_Y578del KIT D816E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23694,
            "profileName": "KIT V560_Y578del KIT A829P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136863,
            "transcript": "XM_005265742",
            "gDna": "chr4:g.54727455_54727511del57",
            "cDna": "c.1678_1734del57",
            "protein": "p.I560_K578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136856,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54727447_54727503del57",
            "cDna": "c.1679_1735del57",
            "protein": "p.V560_Y578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136860,
            "transcript": "XM_017008179",
            "gDna": "chr4:g.54727455_54727511del57",
            "cDna": "c.1678_1734del57",
            "protein": "p.I560_K578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136862,
            "transcript": "XM_017008180",
            "gDna": "chr4:g.54727458_54727514del57",
            "cDna": "c.1678_1734del57",
            "protein": "p.N560_W578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136857,
            "transcript": "NM_001093772",
            "gDna": "chr4:g.54727458_54727514del57",
            "cDna": "c.1678_1734del57",
            "protein": "p.N560_W578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136858,
            "transcript": "XM_005265740",
            "gDna": "chr4:g.54727443_54727499del57",
            "cDna": "c.1678_1734del57",
            "protein": "p.V560_P578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136859,
            "transcript": "XM_005265741",
            "gDna": "chr4:g.54727443_54727499del57",
            "cDna": "c.1678_1734del57",
            "protein": "p.V560_P578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136861,
            "transcript": "XM_017008178",
            "gDna": "chr4:g.54727447_54727503del57",
            "cDna": "c.1679_1735del57",
            "protein": "p.V560_Y578del19",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}